Fentanyl Rehab Cost in Pennsylvania: Protocol, Pricing, and 2026 Reality
Fentanyl rehab in Pennsylvania costs $22,000 to $65,000 for a 30-day inpatient program without insurance, or $8,500 to $24,000 out-of-pocket with PPO insurance. Philadelphia has among the nation’s highest xylazine contamination rates — frequently 90%+ of fentanyl samples tested by Prevention Point Philadelphia, Philadelphia DPH, and DEA surveillance. This dramatically exceeds New York (~31%), New Jersey (~29%), and California (~15%). Fentanyl detox in Pennsylvania runs 10 to 14 days, with low-dose (Bernese) buprenorphine induction standard at academic medical centers and specialized wound care for xylazine necrotic ulcers. PA Medicaid covers the full continuum at $0 for 3.5 million enrollees; PA’s Centers of Excellence (COE) provide integrated care combining MAT, wound care, primary care, and behavioral health.
Pennsylvania — particularly Philadelphia — has been at the leading edge of the xylazine crisis since it emerged in 2019–2020. Kensington has become a national focal point for fentanyl-xylazine harm reduction, clinical protocol development, and policy response. This guide combines PA’s 2015–2024 policy infrastructure (COE model, SCA system, Act 106 parity, $1.07B Opioid Settlement Fund) with fentanyl-specific clinical protocols (Bernese induction, xylazine wound care, alpha-agonist withdrawal management, long-acting MAT).
The PA Fentanyl + Xylazine Reality
Philadelphia Xylazine Rate: Among Highest in the Nation
Philadelphia drug checking data from multiple sources (Prevention Point Philadelphia, Philadelphia Department of Public Health, DEA regional surveillance, academic research) consistently finds xylazine in 90%+ of fentanyl samples tested in Philadelphia in recent years.
Comparison:
- Philadelphia: 90%+
- New York: ~31%
- New Jersey: ~29%
- California: ~15%
- Florida: ~10–15%
- Texas: ~10–15%
Philadelphia was the first major U.S. city to face widespread xylazine contamination (starting around 2019–2020 in Kensington), and clinical protocols for xylazine management were largely developed in response to the Philadelphia crisis.
77% Statewide Fentanyl Involvement
PA DOH 2023: fentanyl involved in 77% of PA opioid overdoses. Philadelphia specifically: 79%.
4,719 PA Overdose Deaths in 2023
- Philadelphia alone: 1,315 (28% of state total)
- Kensington neighborhood: disproportionately affected
- Rural PA: severe access gaps
- Approximately 1 PA death every 2 hours
Clinical Implications
- Longer detox — 10–14 days for fentanyl-xylazine-contaminated patients
- Bernese induction standard at PA academic centers
- Alpha-agonist withdrawal management (clonidine, dexmedetomidine) for xylazine component
- Specialized wound care for xylazine necrotic ulcers — often requiring surgical debridement
- Long-acting MAT (Brixadi weekly, Sublocade monthly) for fentanyl-era retention
- Multiple naloxone doses (4–8 mg) for fentanyl overdose reversal
Why Pennsylvania Is Different for Fentanyl Treatment
1. Philadelphia Xylazine Epicenter
Philadelphia has been at the leading edge of the xylazine crisis since 2019–2020. Clinical protocols for xylazine management were largely developed in Philadelphia.
2. Centers of Excellence (COE) — Integrated Care Model
PA’s 45+ COEs integrate fentanyl treatment with wound care, primary care, hepatitis C treatment, HIV care, mental health, and case management — particularly valuable for fentanyl-xylazine patients.
3. Prevention Point Philadelphia — Nation’s Oldest SSP
Established 1991. Provides sterile syringes, naloxone, fentanyl/xylazine test strips, wound care, MAT referrals. National model for harm reduction.
4. Major Academic Medical Centers
Penn Medicine, Temple Health, Jefferson, UPMC, Allegheny Health Network, Einstein, Geisinger, Penn State Health — national leaders in fentanyl-era clinical protocols.
5. PA Opioid Settlement Fund ($1.07B+)
15% allocated to Philadelphia given disproportionate burden. 70% to counties, 15% to state.
6. Medicaid Expansion (2015) — 3.5 Million Enrollees
Covers full fentanyl continuum at $0 through managed care plans.
7. Act 106 (2024) Parity Enforcement
Strengthened state parity enforcement on top of federal MHPAEA — particularly important for fentanyl given longer detox, wound care needs, and long-acting MAT cost.
8. SCA System for Uninsured Access
47 SCAs serve all 67 counties with publicly-funded fentanyl treatment.
For full Pennsylvania regulatory context, see rehab cost in Pennsylvania. For fentanyl-specific national treatment, see fentanyl rehab cost.
Fentanyl Rehab Cost in PA: 2026 Breakdown
| Level of Care | Duration | Without Insurance | With PPO |
|---|---|---|---|
| Medical detox (fentanyl-only) | 7–10 days | $2,500 – $8,000 | $1,000 – $4,000 |
| Medical detox (fentanyl + xylazine) | 10–14 days | $3,500 – $12,600 | $1,400 – $6,300 |
| Inpatient residential (standard) | 30 days | $22,000 – $32,000 | $8,500 – $15,000 |
| Inpatient residential (mid-tier) | 30 days | $32,000 – $48,000 | $13,000 – $20,000 |
| Main Line / Philly luxury | 30 days | $48,000 – $85,000+ | Capped at OOP max |
| Partial hospitalization (PHP) | 4–6 weeks | $5,000 – $16,000 | Capped at OOP max |
| Intensive outpatient (IOP) | 8–12 weeks | $4,000 – $12,000 | Capped at OOP max |
| MAT ongoing | 12–24+ months | $250 – $1,800/month | $25 – $350/month |
| Xylazine wound care | Variable | $2,000 – $25,000+ per episode | Medical benefit |
Xylazine-Specific Protocols at PA Facilities
Given Philadelphia’s nation-leading xylazine rates (90%+ of fentanyl samples), PA facilities have developed the most advanced xylazine protocols in the U.S.
Clinical Components
- Extended detox (10–14 days)
- Alpha-agonist withdrawal management — clonidine, dexmedetomidine address xylazine sympathetic hyperactivity
- Specialized wound care — xylazine necrotic ulcers can extend to bone; Philadelphia hospitals maintain dedicated wound care teams
- Combined buprenorphine + clonidine + comfort-measures protocols
- Infection screening — MRSA, osteomyelitis; often require ID consult
- Surgical debridement when indicated
- Skin grafts for severe wounds (rare but occurs)
PA Facilities Specializing in Xylazine
- Penn Medicine (HUP, Pennsylvania Hospital, Presbyterian) — academic leader in xylazine research and care
- Temple Health (Temple University Hospital, Episcopal) — Philadelphia safety net with Kensington exposure
- Jefferson Health — Philadelphia academic
- Einstein Medical Center (Philadelphia) — Kensington proximity
- Hahnemann-legacy facilities — historical Kensington care
- Prevention Point Philadelphia — community-based wound care
- UPMC Mercy / UPMC Presbyterian — Pittsburgh academic
- Allegheny General Hospital — Pittsburgh
Bernese Low-Dose Buprenorphine Induction in PA
Protocol Timeline
| Day | Bup Dose | Status |
|---|---|---|
| 1 | 0.5 mg | Continues fentanyl use |
| 2 | 1.0 mg | Continues fentanyl use |
| 3 | 2.0 mg | Begins reducing fentanyl |
| 4 | 4.0 mg | Further reduces fentanyl |
| 5 | 8.0 mg | Discontinues fentanyl |
| 6–7 | 12–16 mg | Titrate to therapeutic dose |
PA Facilities Using Bernese Induction
- Penn Medicine Addiction Medicine — HUP, Pennsylvania Hospital, Presbyterian
- Temple Health Addiction Medicine
- Jefferson Health Addiction Medicine
- UPMC Addiction Medicine — multiple Pittsburgh hospitals
- Allegheny Health Network
- Einstein Medical Center
- Geisinger Medical Center
- Penn State Hershey Medical Center
- Lehigh Valley Health Network
- St. Luke’s University Health (Bethlehem)
- Growing number of community residential providers
Ask facilities directly about low-dose induction availability.
Prevention Point Philadelphia
Nation’s oldest syringe service program. Located in Kensington at the epicenter of the fentanyl-xylazine crisis. Services:
- Sterile syringes
- Naloxone distribution — thousands of kits annually
- Fentanyl and xylazine test strips
- Wound care — dedicated staff for xylazine necrotic ulcers
- Hepatitis C screening
- HIV testing and PrEP referral
- Connection to MAT and treatment
- Peer support
- Drug checking (Philadelphia Department of Public Health partnership)
Prevention Point has reversed thousands of overdoses and connects thousands annually to treatment. A national model for harm reduction infrastructure.
Long-Acting MAT for PA Fentanyl Patients
Fentanyl-era relapse is catastrophic — a single slip often results in overdose. Long-acting MAT is particularly valuable in PA given the potent supply.
| Medication | Dosing | PA Self-Pay | PA Insured | PA Medicaid |
|---|---|---|---|---|
| Brixadi (weekly) | Weekly injection | $600 – $1,800/mo | $50 – $350/mo | $0 – $10 |
| Brixadi (monthly) | Monthly injection | $1,600 – $1,800/mo | $50 – $350/mo | $0 – $10 |
| Sublocade (monthly) | Monthly injection | $1,600 – $1,800/mo | $50 – $300/mo | $0 – $10 |
| Vivitrol (monthly) | Monthly naltrexone | $1,300 – $1,700/mo | $0 – $300/mo | $0 – $10 |
Brixadi weekly is particularly valuable in early recovery. Ask facilities whether Brixadi is on formulary.
ED-Initiated Buprenorphine Bridges at PA Hospitals
Major PA hospitals have operational ED-bup bridge programs:
- Penn Medicine — multiple Philadelphia hospitals
- Temple University Hospital (Philadelphia)
- Jefferson Health (Philadelphia)
- Einstein Medical Center (Philadelphia)
- UPMC Mercy / UPMC Presbyterian (Pittsburgh)
- Allegheny General Hospital (Pittsburgh)
- Geisinger Medical Center (Danville)
- Penn State Hershey Medical Center
- Lehigh Valley Hospital-Cedar Crest (Allentown)
- St. Luke’s University Health (Bethlehem)
Research (JAMA 2023) shows dramatic improvements in 6-month retention. Ask in the ED: “Is there an ED-initiated buprenorphine bridge program?”
PA Opioid Settlement Fund Deployment
PA’s $1.07B+ settlement share over 18 years managed by PA Opioid Misuse and Addiction Abatement Trust:
- 70% to counties — local fentanyl response
- 15% to state — DDAP-administered programs
- 15% to Philadelphia — given disproportionate burden
Deployment priorities:
- MAT expansion in underserved counties
- COE capacity expansion for integrated fentanyl-xylazine care
- Naloxone and fentanyl/xylazine test strip distribution
- Wound care program expansion (Philadelphia focus)
- Recovery support services
- Residential fentanyl treatment expansion
- Workforce development for addiction medicine
- Harm reduction infrastructure
How Do Pennsylvanians Afford Fentanyl Rehab?
1. PA Medicaid (3.5M Enrollees)
Full continuum + wound care at $0 through managed care plans.
2. Private Commercial Insurance
Highmark BCBS, Independence Blue Cross, UPMC Health Plan, Geisinger, Aetna, UHC. Capped at $7,000–$9,500 OOP max.
3. Single County Authorities (SCAs)
47 SCAs, 67 counties. Call 1-800-662-4357.
4. PA Opioid Settlement Fund Programs
Counties + state + Philadelphia-specific.
5. Gaudenzia Nonprofit Network
30+ PA locations. Sliding scale.
6. Pennie (PA Marketplace)
Subsidized premiums.
7. Prevention Point Philadelphia + Other SSPs
Harm reduction + MAT referral.
8. Centers of Excellence (COE)
Integrated care funded by PA Medicaid.
Choosing a PA Fentanyl Rehab
Verification questions before admission:
- Is the facility DDAP-licensed? Verify via Treatment Atlas
- Is the facility accredited?
- Is the facility in-network for my plan?
- Do you offer low-dose (Bernese) buprenorphine induction?
- Do you have xylazine-specific protocols and wound care capacity?
- Is Brixadi weekly on formulary?
- Are you a Center of Excellence (COE)?
- What’s the MAT continuation plan at discharge?
- Are you an SCA-contracted provider (if uninsured)?
- What’s my deductible and OOP max, and what’s met year-to-date?
Pennsylvania Fentanyl Resources
State and City Resources
- PA Get Help Now Helpline: 1-800-662-4357 (24/7)
- PA DDAP: pa.gov/agencies/ddap
- Philadelphia DBHIDS: 215-685-6440
- Philadelphia DPH: phila.gov/health
- SAMHSA National Helpline: 1-800-662-4357
- 988 Suicide & Crisis Lifeline: 988
Harm Reduction
- Prevention Point Philadelphia — Kensington SSP (oldest in nation)
- PA DOH Project Free Naloxone
- Participating PA pharmacies — no-prescription naloxone
- Philadelphia DPH Drug Checking Program
Major Counties
- Philadelphia: 215-685-6440 (DBHIDS)
- Allegheny County (Pittsburgh): 412-350-4457
- Montgomery / Bucks / Chester / Delaware: 211
- Lehigh Valley: 211
- Dauphin (Harrisburg): 211
Success Rate Reality
Fentanyl use disorder recovery rates depend on MAT continuation:
- With MAT for 12+ months: 40–60% sustained recovery
- Without MAT: 10–30%
- MAT reduces overdose-death risk by ~50% (NIDA)
- Treatment retention 2–4x higher on MAT
For fentanyl specifically, long-acting MAT (Brixadi, Sublocade) typically outperforms daily dosing because fentanyl-era relapse is catastrophic.
Recovery is a chronic-disease process. Most fentanyl patients require multiple treatment episodes.
Final Thoughts
Pennsylvania — particularly Philadelphia — is the national epicenter of the fentanyl-xylazine crisis. The clinical protocols for xylazine management, the Centers of Excellence integrated care model, and Prevention Point Philadelphia’s harm reduction work were largely developed in response to the Philadelphia crisis. PA’s policy stack (Medicaid expansion, SCA system, Treatment Atlas, Act 106, $1.07B Opioid Settlement Fund) provides strong coverage, though the Kensington crisis remains severe.
Five steps:
- Call PA Get Help Now: 1-800-662-4357 (24/7)
- Check PA Medicaid eligibility — 3.5M qualify for $0 coverage including wound care
- Ask about Centers of Excellence (COE) for integrated fentanyl-xylazine care
- Ask about Bernese induction + Brixadi weekly + xylazine wound care at admitting facility
- Use ED-bup bridge if in an ED after overdose
For broader context, see rehab cost in Pennsylvania, fentanyl rehab cost, opioid rehab cost in Pennsylvania, medical detox cost, and does insurance cover rehab.
Sources
- Philadelphia Department of Public Health. “Drug Supply Surveillance.” 2023–2024.
- Pennsylvania Department of Health. “Drug Overdose Data.” 2023.
- Prevention Point Philadelphia. “Services and Impact Reports.” 2024.
- Drug Enforcement Administration. “National Drug Threat Assessment.” 2024.
- Pennsylvania Act 106 (2024). “Mental Health and Substance Use Disorder Parity.”
- PA Opioid Misuse and Addiction Abatement Trust. 2024.
- PA DDAP. “Centers of Excellence Model.” 2016–2024.
- Randhawa PA, et al. “Buprenorphine Low-Dose Induction (Bernese Method).” Journal of Addiction Medicine. 2024.
- D’Onofrio G, et al. “Emergency Department–Initiated Buprenorphine.” JAMA. 2023.
- Friedman JR, et al. “Xylazine contamination of the opioid supply.” 2023.
- National Institute on Drug Abuse. “Fentanyl DrugFacts.” 2024.
- American Society of Addiction Medicine. “Clinical Practice Guideline for the Treatment of Opioid Use Disorder.” 2020.
- Philadelphia DBHIDS. “Behavioral Health Services.” 2024.
- U.S. Department of Labor. “Mental Health Parity and Addiction Equity Act Final Rule (September 2024).”
- SAMHSA Behavioral Health Treatment Services Locator. 2025. https://findtreatment.samhsa.gov/
Fentanyl Treatment in Pennsylvania — Is Your Plan Enough?
Even with insurance, many people discover their plan doesn't cover residential treatment at the level they need. A broker who specializes in behavioral health coverage can review your situation and find a plan that works.
Call 1-866-454-9577Free Consultation · No Obligation
Prodest Insurance Group is a licensed, independent health insurance brokerage. Calling the number above connects you with a licensed insurance agent, not a treatment facility. Insurance placement is a separate service from treatment referral.
Frequently Asked Questions
How much does fentanyl rehab cost in Pennsylvania?
Fentanyl rehab in Pennsylvania costs $22,000–$65,000 for 30 days of inpatient treatment without insurance, or $8,500–$24,000 out-of-pocket with PPO insurance (capped at the 2026 OOP max of $7,000–$9,500). Medical detox adds $3,500–$12,600 (10–14 days — longer than pure-opioid detox because Philadelphia has among the nation's highest xylazine contamination rates in fentanyl samples, frequently 90%+, requiring extended monitoring, wound care, and often low-dose Bernese buprenorphine induction). Long-acting MAT (Brixadi weekly, Sublocade monthly) costs $50–$350/month insured; $600–$1,800 self-pay. PA Medicaid (3.5 million enrollees) covers the full fentanyl treatment continuum at $0. PA's Centers of Excellence (COE) integrate fentanyl treatment with primary care, wound care, and behavioral health — a national model.
How much xylazine is in Philadelphia's drug supply?
Philadelphia has among the nation's highest xylazine contamination rates — published research and drug checking data from Prevention Point Philadelphia, the Philadelphia Department of Public Health, and DEA surveillance have found xylazine in 90%+ of fentanyl samples tested in recent years. This dramatically exceeds other major cities: New York (~31%), New Jersey (~29%), California (~15%). The Kensington neighborhood has been a leading indicator for the xylazine crisis — xylazine first became a significant issue in Philadelphia's drug supply around 2019–2020 before spreading nationally. Xylazine is a veterinary sedative (alpha-2 adrenergic agonist), not an opioid: naloxone does not reverse xylazine sedation, and withdrawal requires alpha-agonists (clonidine, dexmedetomidine). Injection produces characteristic necrotic ulcers that can require surgical debridement. Philadelphia hospitals (Penn, Temple, Jefferson, Einstein) have integrated wound care with addiction medicine in response.
How long does fentanyl detox take in Pennsylvania?
Fentanyl detox in Pennsylvania typically takes 10–14 days — longer than the 5–7 day detox for pure heroin or 7–10 days for fentanyl-only. The extended duration reflects Philadelphia's xylazine contamination (frequently 90%+ of fentanyl samples) which adds a distinct withdrawal syndrome requiring alpha-agonists. Fentanyl is highly lipophilic (fat-soluble) and accumulates in body tissues, so elimination is prolonged and withdrawal symptoms can appear delayed or extended. Traditional COWS-threshold buprenorphine induction frequently causes precipitated withdrawal in fentanyl-contaminated patients, which is why Pennsylvania academic medical centers (Penn Medicine, Temple Health, Jefferson, UPMC, Allegheny Health Network, Geisinger, Einstein) use low-dose (Bernese) induction — starting at 0.5 mg bup and titrating up over 5–7 days while the patient continues fentanyl use, then transitioning.
Does Pennsylvania Medicaid cover fentanyl treatment?
Yes, comprehensively. PA Medicaid (Medical Assistance) covers the full fentanyl treatment continuum at $0 cost for 3.5 million enrollees through managed care plans (AmeriHealth Caritas, Highmark Wholecare, UPMC for You, Keystone First, Geisinger Health Plan). Covered services: medical detox (up to 14+ days including xylazine-specific protocols), inpatient residential treatment, PHP, IOP, standard outpatient, all FDA-approved MAT medications (especially valuable for fentanyl-era patients — Brixadi weekly injection, Sublocade monthly injection, Suboxone, methadone through OTPs, Vivitrol), wound care for xylazine-contaminated fentanyl patients, and Centers of Excellence (COE) integrated care. PA does not require prior authorization for generic buprenorphine initiation. Apply for PA Medicaid at [compass.state.pa.us](https://www.compass.state.pa.us/) or 1-866-550-4355.
What is Kensington's fentanyl crisis?
Kensington is a Philadelphia neighborhood that became a national epicenter of the fentanyl-xylazine crisis starting around 2019–2020. Philadelphia recorded 1,315 drug overdose deaths in 2023 — 28% of Pennsylvania's state total — with 79% involving fentanyl and xylazine contamination reaching 90%+ of samples tested. Kensington is disproportionately affected: open-air drug markets operate in the neighborhood, concentrated homelessness creates a 'recovery wall' barrier, and the fentanyl-xylazine supply has produced an epidemic of necrotic wounds requiring surgical care. Philadelphia has responded with: Prevention Point Philadelphia (nation's oldest syringe service program) providing naloxone, fentanyl test strips, wound care, MAT referrals; ED-initiated buprenorphine bridges at Penn, Temple, Jefferson, Einstein, Hahnemann-legacy hospitals; Philadelphia Department of Public Health drug checking programs; and PA Opioid Settlement Fund 15% allocation to Philadelphia given disproportionate burden. Structural challenges (housing instability, trafficking, racial disparities) persist.
What is Bernese low-dose buprenorphine induction?
Bernese low-dose (micro-dose) buprenorphine induction is a protocol that starts buprenorphine at very low doses (0.5 mg) while the patient is still using a full opioid agonist like fentanyl, then gradually titrates up over 5–7 days before discontinuing the full agonist. This avoids precipitated withdrawal — a dangerous complication that occurs when traditional COWS-threshold induction is attempted in patients with high fentanyl tissue load. Because fentanyl is fat-soluble and accumulates in body tissues, fentanyl-contaminated opioid users often experience precipitated withdrawal with traditional induction. Bernese protocols are now preferred at Pennsylvania academic medical centers: Penn Medicine (Hospital of the University of Pennsylvania, Pennsylvania Hospital, Presbyterian), Temple Health, Jefferson Health, UPMC (multiple Pittsburgh hospitals), Allegheny Health Network, Einstein Medical Center, Geisinger Medical Center, and a growing number of community residential providers. Ask facilities directly about low-dose induction availability.
What are PA Centers of Excellence (COE) for fentanyl treatment?
Pennsylvania's Centers of Excellence (COEs) are integrated care programs launched in 2016 as a national model for OUD treatment — particularly valuable for fentanyl-era patients with xylazine wound care needs, co-occurring hepatitis C, HIV, endocarditis, or mental health conditions. COEs combine: (1) MAT (buprenorphine, methadone, Vivitrol) including Bernese induction; (2) primary care for hepatitis C, HIV, cardiac, wound care, and other medical complications; (3) behavioral health services; (4) case management and care coordination; (5) peer recovery support; (6) social services navigation (housing, employment, legal). PA has 45+ designated COEs serving urban and rural areas, funded through PA Medicaid. For fentanyl-era patients — particularly those with xylazine wound complications — COE integrated care substantially outperforms fragmented services. Ask your SCA or Medicaid managed care plan for nearest COE.
What is Prevention Point Philadelphia?
Prevention Point Philadelphia (PPP) is the nation's oldest syringe service program (SSP), established in 1991 and operating in the Kensington neighborhood at the epicenter of the Philadelphia fentanyl-xylazine crisis. PPP provides: sterile syringes, naloxone distribution, fentanyl and xylazine test strips, hepatitis C screening, HIV testing, wound care for xylazine necrotic ulcers (a specialty given Philadelphia's crisis), connection to MAT and treatment, HIV PrEP referral, peer support, and Philadelphia Department of Public Health drug checking program participation. PPP has reversed thousands of overdoses and connects thousands annually to treatment. The program operates under Pennsylvania's authorization framework for SSPs (varying legal structure by county — more established in Philadelphia and Allegheny than some other areas). PPP is a pioneer and national model for harm reduction infrastructure.
How does Act 106 affect fentanyl treatment in Pennsylvania?
Pennsylvania's Act 106 of 2024 strengthened mental health parity enforcement — a significant protection for fentanyl treatment given the longer detox (10–14 days for fentanyl-xylazine), more complex medical needs (wound care, hep C), and higher cost profile. Act 106 ensures commercial insurers comply with federal MHPAEA for fentanyl-era OUD treatment, preventing arbitrary cost-sharing, visit limits, or prior-authorization requirements on fentanyl care that are more restrictive than medical/surgical benefits. For fentanyl specifically, Act 106 is especially important because: (1) post-discharge overdose risk is catastrophic (tolerance loss + potent supply); (2) longer detox requires more days of authorized coverage; (3) xylazine wound care requires coordination with medical benefit; (4) long-acting MAT (Brixadi, Sublocade) has high monthly cost requiring parity. Combined with the 2024 federal MHPAEA final rule, Pennsylvanians have strong layered parity protection for fentanyl treatment claims.